Anlon Healthcare

Anlon Healthcare's board approved a proposal to raise up to Rs250 crore through fully convertible warrants issued on a preferential basis for cash consideration. The warrants, convertible into equity shares of Rs2 face value, were earmarked for two promoters, Punitkumar Rasadia and Meet Vachhani, and two public investors, Smart Horizon Capital Advisors and Ploutos Plus Consultant, with pricing and the shareholder meeting date to be fixed at a later board meeting. The company reported consolidated revenue of Rs171.97 crore in FY26 with negative operating cash flow of Rs79.44 crore as inventories and receivables built up. Net worth stood at Rs209.77 crore with light post-IPO leverage, though bank limits were 76.74% drawn and cash was Rs3.41 crore. Shareholders had approved on 5 September the acquisition of further stakes in ApiQo Organics and Bizotic Lifescience through a preferential share swap at Rs17.85 per share.

Powered by Tijori

Anlon Healthcare corrected the shareholding percentages it expected to acquire in Apiqo Organics and Bizotic Lifescience to 44.94% and 47.41%, respectively, from 32.52% and 43.33%. The proposed acquisitions remained structured as non-cash share swaps, valued at about ₹116.52 crore for AOPL and ₹36.78 crore for BLPL, with up to 8.59 crore Anlon shares to be issued at ₹17.85 each. AOPL and BLPL reported FY26 turnover of ₹72.54 crore and ₹31.27 crore, respectively, and both transactions were subject to approvals and expected to be completed within 90 days. Anlon's consolidated FY26 revenue was ₹172.22 crore, while standalone Q1 FY27 revenue was ₹30.98 crore.

Powered by Tijori

Anlon Healthcare executed share-swap agreements to acquire up to 32.52% of Apiqo Organics and 43.33% of Bizotic Lifescience for aggregate consideration of about ₹153.3 crore. It proposed issuing up to 8.59 crore new equity shares at ₹17.85 each, subject to approvals and acceptance by the target shareholders, with no cash consideration expected. Apiqo, which manufactures pharmaceutical intermediates and industrial and fine chemicals, reported FY26 turnover of ₹72.5 crore, while Bizotic, an API and contract research and manufacturing business, reported ₹31.3 crore. Anlon's consolidated FY26 revenue was ₹172.2 crore and profit after tax was ₹29.1 crore after an acquisition-led expansion of the group.

Powered by Tijori

March 6 (Reuters) - Anlon Healthcare Ltd ANLN.NS:

• APPROVES ISSUE OF BONUS SHARES IN THE RATIO OF 1:1

• SUB-DIVISION OF EACH SHARE INTO 5 SHARES

Source text: ID:nnAZN4SJW7D

Further company coverage: ANLN.NS

(([email protected];;))

Feb 9 (Reuters) - Anlon Healthcare Ltd ANLN.NS:

• ANLON HEALTHCARE LTD - APPOINTMENT OF NAIMISH DILIPBHAI BHATT AS CFO

Source text: ID:nNSE7bv26J

Further company coverage: ANLN.NS

(([email protected];))

** Shares of Anlon Healthcare ANLN.NS rise 6.3% to 142.99 rupees

** Pharma co says it has developed two new anti-malarial products, Artemether and Lumefantrine

** Both to be launched in November

** Stock set to gain for fifth straight session

** ANLN up nearly 55% from trading debut open price September 3

(Reporting by Vijay Malkar)

(([email protected];))